Supplementary Material

Supplementary Figure 1  Design of the PALACE 1, 2, and 3 studies. *All doses were titrated over the first week of treatment. †Patients whose swollen and tender joint counts had not improved by ≥20% at Week 16 were considered non-responders and were required to be re-randomised (1:1) to apremilast 30 mg twice daily or 20 mg twice daily if they were initially randomised to placebo. Apremilast-treated patients remained on their initial dose. ‡At Week 24, all remaining placebo patients were re-randomised to apremilast 30 mg twice daily or 20 mg twice daily. ACR20, 20% improvement in American College of Rheumatology response criteria; BSA, body surface area; DMARD, disease-modifying anti-rheumatic drug.